SCHEMBL5243227

SCHEMBL5243227

O=S(=O)(Nc1cccc(F)c1)c1ccc(F)c2nonc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
PFKFB3 Q16875 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
TET2 Q6N021 1/20 0.44
PKM P14618 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ESR1 P03372 1/20 0.44
HDAC4 P56524 1/20 0.43
TSHR P16473 1/20 0.43
RORA P35398 1/20 0.42
RORC P51449 1/20 0.42
NR1H2 P55055 1/20 0.42
TP53 P04637 1/20 0.42
HSPD1 P10809 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN5 P54829 1/20 0.42
HSPE1 P61604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5279927 0.87 PFKFB3 (0.62) KMT2APOLBPFKFB3SMN1; SMN2PKM
SCHEMBL5277982 0.86 EPAS1 (0.51) KMT2APOLBPFKFB3SMN1; SMN2PKM
SCHEMBL5281454 0.84 KMT2A (0.70) KMT2APOLBSMN1; SMN2ALDH1A1TP53
SCHEMBL5293227 0.77 KMT2A (0.54) KMT2APOLBSMN1; SMN2ALDH1A1
SCHEMBL5278920 0.77 POLB (0.57) KMT2APOLBSMN1; SMN2TET2PKM
SCHEMBL6390668 0.75 KMT2A (0.68) KMT2APOLBSMN1; SMN2ALDH1A1HSPD1
SCHEMBL5299664 0.75 RORA (0.61) KMT2APOLBPFKFB3SMN1; SMN2ALDH1A1
SCHEMBL5280702 0.74 KMT2A (0.46) KMT2APOLBPFKFB3RORARORC
SCHEMBL6394115 0.73 KMT2A (0.64) KMT2APOLBSMN1; SMN2ALDH1A1HSPD1
SCHEMBL6397094 0.73 ALDH1A1 (0.54) KMT2APOLBSMN1; SMN2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed
US-6946481-B1 Endothelin antagonists ABBOTT LABORATORIES (US) 2005-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885POLB 2997/4885PFKFB3 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.